Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs

Tuberculosis

Volumn 88, Issue 5, 2008, Pages 410-419

  Chung, Woo Jin ^a   Kornilov, Andrei ^a   Brodsky, Benjamin H ^a   Higgins, Michael ^b   Sanchez, Tracy ^b   Heifets, Leonid B ^b   Cynamon, Michael H ^c   Welch, John ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Macrophage; Morphazinamide; Murine models; Pyrazinamide; Resistance

Indexed keywords

N (DIBUTYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (DIETHYLAMINOMETHYL) 5 METHYLPYRAZINE 2 CARBOXAMIDE; N (DIETHYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (DIPROPYLAMINOMETHYL) 5 METHYLPYRAZINE 2 CARBOXAMIDE; N (DIPROPYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (MORPHOLIN 4 YLMETHYL) 5 METHYLPYRAZINE 2 CARBOXAMIDE; N (N' BENZYL, N' METHYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (N' BUTYL, N' ETHYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (N' BUTYL, N' METHYLAMINOMETHYL)PYRAZINE 2 CARBOXAMIDE; N (PIPERAZIN 1 YLMETHYL) 5 METHYLPYRAZINE 2 CARBOXAMIDE; N (PIPERAZIN 1 YLMETHYL)PYRAZINE 2 CARBOXAMIDE; N (PIPERIDIN 1 YLMETHYL)PYRAZINE 2 CARBOXAMIDE; N (PYRROLIDIN 1 YLMETHYL) 5 METHYLPYRAZINE 2 CARBOXAMIDE; N (PYRROLIDIN 1 YLMETHYL)PYRAZINE 2 CARBOXAMIDE; PYRAZINAMIDE; PYRAZINE DERIVATIVE; RIFAMYCIN;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MACROPHAGES; MICE; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TREATMENT OUTCOME;

EID: 49349115587     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2008.06.001     Document Type: Article

References (88)

1. Maartens G., and Wilkinson R.J. Tuberculosis. Lancet 370 (2007) 2030-2043
2. Sacchettini J.C., Rubin E.J., and Freundlich J.S. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 6 (2008) 41-52
3. Janin Y.L. Antituberculosis drugs: ten years of research. Bioorg Med Chem 15 (2007) 2479-2513
4. Ginsberg A.M., and Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 13 (2007) 290-294
5. Chorine V. Action of nicotinamide on bacilli of the species Mycobacterium. C R Acad Sci 220 (1945) 150-151
6. McKenzie D., Malone L., Kushner S., Oleson J.J., and Subbarow Y. The effect of nicotinic acid amide on experimental tuberculosis of white mice. J Lab Clin Med 33 (1949) 1249-1253
7. Kushner S., Dalalian H., Sanjurjo J.L., Bach F.L., Safir S.R., Smith V.K., et al. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 74 (1952) 3617-3621
8. Heifets L.B. Pyrazinamide. In: Yu V.L., Merigan T.C., and Barriere S.L. (Eds). Antimicrobial therapy and vaccines (1999), Williams and Wilkins, Baltimore, MD 668-676
9. Zhang Y., and Mitchison D.A. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7 (2003) 6-21
10. Wade M.M., and Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 9 (2004) 975-994
11. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66 (1985) 219-226
12. Steele M.A., and Des Prez R.M. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94 (1988) 845-850
13. Jindani A., Nunn A.J., and Enarson D.A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364 (2004) 1244-1251
14. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M.H., et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41 (1997) 540-543
15. Konno L., Feldmann F.M., and McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Resp Dis 95 (1967) 461-469
16. Scorpio A., and Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2 (1996) 662-667
17. Heifets L.B., Flory M.A., and Lindholm-Levy P.J. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?. Antimicrob Agents Chemother 33 (1989) 1252-1254
18. Speirs R.J., Welch J.T., and Cynamon M.H. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob Agents Chemother 39 (1995) 1269-1271
19. Raynaud C., Laneelle M.A., Senaratne R.H., Draper P., Laneelle G., and Daffe M. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145 Pt 6 (1999) 1359-1367
20. Zimhony O., Vilcheze C., Arai M., Welch J.T., and Jacobs Jr. W.R. Pyrazinoic acid and its n-propyl ester inhibit Fatty Acid Synthase Type I in replicating tubercle bacilli. Antimicrob Agents Chemother 51 (2007) 752-754
21. Ngo S.C., Zimhony O., Chung W.J., Sayahi H., Jacobs Jr. W.R., and Welch J.T. Inhibition of isolated Mycobacterium tuberculosis Fatty Acid Synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 51 (2007) 2430-2435
22. Cynamon M.H., Gimi R., Sharpe C.A., Bergmann K.E., Gyenes F., and Welch J.T. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J Med Chem 20 (1995) 3902-3907
23. Cynamon M.H., Speirs R.J., and Welch J.T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 42 (1998) 462-463
24. Bergmann K.E., Cynamon M.H., and Welch J.T. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J Med Chem 39 (1996) 3394-3400
25. Yamamoto S., Toida I., Watanabe N., and Ura T. In vitro antimycobacterial activities of pyrazinamide analogs. Antimicrob Agents Chemother. 39 (1995) 2088-2091
26. Wachter G.A., Davis M.C., Martin A.R., and Franzblau S.G. Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. J Med Chem 41 (1998) 2436-2438
27. Gezginci M.H., Martin A.R., and Franzblau S.G. Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2. J Med Chem 44 (2001) 1560-1563
28. S.p.A. BIC. N-(Morpholinomethyl)amide of pyrazinecarboxylic acid. Belgium; 1962.
29. Bonati F., and Bertoni L. Basic derivatives of pyrazine-2-carboxylic acid with antimycobacterial action. Microbiological and pharmacological study. Minerva Med 53 (1962) 1704-1708
30. Havel A., Trnka L., and Urbancik R. Resistance and its delay as criterion of the antimycobacterial activity of morphazinamide and pyrazinamide under experimental conditions. Rozhl Tuberk 27 (1967) 162-166
31. Solov'ev V.N., and Pavlov E.P. Significance of intracellular medium for antimycobacterial activity of some pyrazine-2-carboxylic acid derivatives. Chemotherapia 11 (1966) 345-354
32. Solov'ev V.N., and Pavlov E.P. Antituberculous properties of some pyrazinecarboxylic acid derivatives. Farmakol Toksikol (Moscow) 30 (1967) 734-737
33. Bertoni L., and Brega A. Effect of pyrazinamde and morpholinomethyl pyrazinamide in the intracellular neutralization of tubercle bacilli in macrophages. Clin Med 72 (1965) 1006-1012
34. Lucchesi M., Fantoli U., Zubiani M., Lucchesi M., Fantoli U., and Zubiani M. Bacteriological and pharmacological kinetic aspects of morphazinamide bacteriological and pharmacological kinetic aspects of morphazinamide. Minerva Med 56 (1965) 2771-2776
35. Rozewska M. Comparison of the therapeutic action of morphazinamide and pyrazinamide associated with ethionamide in experimental tuberculosis in guinea pigs. G Ital Chemioter 14 (1967) 49-57
36. Casalone G., Denti F., and Rimoldi R. Clinical experience with morphazinamide. Minerva Med 56 (1965) 2900-2905
37. Daddi G. Results of the treatment of tuberculosis with the new drugs isoxyl, ethambutol, rifamycin, and morphazinamide. Wien Med Wochenschr 117 (1967) 266-268
38. Freerksen E., Boenicke R., and Rosenfeld M. Comparative studies of tuberculostatic activity of N-morpholinomethyl pyrazinamide and pyrazine 2-carboxamide in vitro and in vivo. Arzneimittel Forsch 13 (1963) 722-724
39. Zierski M. Metabolism of morphazinamide in patients with pulmonary tuberculosis metabolism of morphazinamide in patients with pulmonary tuberculosis. Minerva Med 56 (1965) 2759-2762
40. Zierski M., and Gajewska E. Metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis. Gruzlica 33 (1965) 773-779
41. Felder E., and Tiepolo U. Aminomethyl amides of pyrazinecarboxylic acids - (I) latent forms of chemotherapeutically active principles. Arzneimittel Forsch 14 (1964) 1225-1227
42. Pavlov E.P. Specificity of antituberculous action in vitro of pyrazine-2-carboxylic acid derivatives. Probl Tuberk (1971) 76-79
43. Castelli D., Vercellino E., and Vercellino A. Role of formaldehyde in the antimycobacterial action of morphazinamide in vitro. G Ital Mal Torace 20 (1966) 261-264
44. Gialdroni-Grassi G., and Grassi C. Metabolic degradation of morphazinamide metabolic degradation of morphazinamide. Minerva Med 56 (1965) 2762-2771
45. Bravo T.C., Ellard G.A., and Mitchison D.A. Reappraisal of the activity of morphazinamide against M. tuberculosis. Tubercle 56 (1975) 211-217
46. Lucchesi M. The antituberculous activity of morphazinamide. G Ital Chemioter 10 (1963) 58-64
47. Mariani B. Hepatotoxicity and tuberculosis therapy, lack of hepatotoxicity of morphazinamide. Progress in antimicrobial and anticancer chemotherapy. Proceedings of the 6th International Congress on Chemotherapy, Baltimore MD; 1969, p. 617-20.
48. Mariani B. Observations in humans and animals of hepatic function, gastric secretion, and uricemia during morphazineamide therapy. Minerva Med 56 (1965) 2782-2788
49. Zitkova L., Stastna J., Tousek J., and Viklicky J. Toxicity of morphazinamide compared with pyrazinamide. Czech Med 6 (1983) 140-151
50. Heifets L., Higgins M., and Simon B. Pyrazinamide is not active against M. tuberculosis in human monocyte-derived macrophages. Int J Tuberc Lung Dis 4 (2000) 491-495
51. Mor N., Simon B., and Heifets L. Methods for determining concentrations of antimicrobial agents in human monocytes. J Chemother 7 (1995) 207-209
52. Mor N., Vanderkolk J., and Heifets L. Inhibitory and bactericidal activities of levofloxacin against M. tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 38 (1994) 1161-1164
53. Boyle J.J., Weissberg P.L., and Bennett M.R. Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 23 (2003) 1553-1558
54. Duffield J.S., Ware C.F., Ryffel B., and Savill J. Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages. Am J Pathol 159 (2001) 1397-1404
55. Song E., Ouyang N., Horbelt M., Antus B., Wang M., and Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 204 (2000) 19-28
56. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., and Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259 (1993) 1739-1742
57. McDermott W., and Tompett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70 (1954) 748-754
58. Zhang Y., Permar S., and Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51 (2002) 42-49
59. Wade M.M., and Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53 (2004) 769-773
60. Somoskovi A., Wade M.M., Sun Z., and Zhang Y. Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother 53 (2004) 192-196
61. Salfinger M., and Heifets L.B. Determination of pyrazinamide MIC at different pHs by the radiometric method. Antimicrob Agents Chemother. 32 (1988) 1002-1004
62. Zhang Y., Scorpio A., Nikaido H., and Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181 (1999) 2044-2049
63. Good R.C., Silcox V.A., Kilborn J.O., and Plikaytis B.D. Identification and drug susceptibility test results for Mycobacteria species. Clin Microbiol Newslett 7 (1985) 133-136
64. Zhang Y., Zhang H., and Sun Z. Susceptibility of Mycobacterium tuberculosis to weak acids. J Antimicrob Chemother 52 (2003) 56-60
65. Wade M.M., and Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 58 (2006) 936-941
66. Crowle A.J., Sbarbaro J.A., and May M.H. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134 (1986) 1052-1055
67. Mackaness G.B. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc 74 (1956) 718-728
68. Salfinger M., Crowle A.J., and Reller L.B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 162 (1990) 201-207
69. Salfinger M., and Crowle A.J. Bestimmung der empfindlichkeit von Tuberkulosebacterien gegenüber Pyrazinamid mit Hilfe humaner Makophagenkultur. Pneumologie 44 (1990) 460-461
70. Carlone N.A., Acocella G., Cuffini A.M., and Forno-Pizzoglio M. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am Rev Resp Dis 132 (1985) 1274-1277
71. Acocella G., Carlone N.A., Cuffini A.M., and Cavallo G. The penetration of rifampacin, pyrazinamide, and pyrazinoic acid into mouse macrophages. Am Rev Resp Dis 132 (1985) 1268-1273
72. Sprick M.G. Phagocytosis of M. tuberculosis and M. smegmatis stained with indicator dyes. Am Rev Tuberc 74 (1956) 552-565
73. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., et al. Lack of acidification in Mycobacterium phagosome produced by exclusion of the vesicular proton-ATPase. Science 263 (1994) 678-681
74. Rastogi N., Potar M.C., and David H.L. Pyrazinamide is not effective against intracellularly growing M. tuberculosis. Antimicrob Agents Chemother 32 (1988) 287-288
75. 3. Antimicrob Agents Chemother 34 (1990) 2217-2222
76. Sbarbaro J.A., Iseman M.D., and Crowle A.J. The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Resp Dis 146 (1992) 1448-1451
77. Sbarbaro J.A., Iseman M.D., and Crowle A.J. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis 77 (1996) 491-495
78. Society BT. A controlled trial of 6 months chemotherapy in pulmonary tuberculosis. Final report: results during 36 months after the end of chemotherapy and beyond. Br J Dis Chest 78 (1984) 330-336
79. Singapore Tuberculosis Service/British Medical Research Council Stsbmr. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 119 (1979) 579-585
80. Snider D.E., Graczyk J., Bek E., and Rogowski J. Supervised six months treatment of newly diagnosed pulmonary tuberculosis using isonizid, rifampicin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130 (1984) 1091-1094
81. Snider D.E., Rogowski J., Zierski M., Bek E., and Long M.W. Successful intermittent treatment of smear positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am Rev Respir Dis 125 (1982) 265-267
82. Klemens S.P., Sharp C.A., and Cynamon M.H. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother 40 (1996) 14-16
83. McCune Jr. R.M., Tompsett R., and McDermott W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique: II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104 (1956) 763-802
84. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Against Tuberc 53 (1978) 5-12
85. Klemens S.P., Grossi M.A., and Cynamon M.H. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 38 (1994) 2245-2248
86. Kelly B.P., Furney S.K., Jessen M.T., and Orme I.M. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 40 (1996) 2809-2812
87. Lenaerts A.M., Chase S.E., and Cynamon M.H. Evaluation of Rifalazil in a combination treatment regimen as an alternative to Isoniazid-Rifampin therapy in a mouse tuberculosis model. Antimicrob Agents Chemother 44 (2000) 3167-3168
88. Shoen C.M., Chase S.E., DeStefano M.S., Harpster T.S., Chmielewski A.J., and Cynamon M.H. Evaluation of Rifalazil in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 44 (2000) 1458-1462